Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

InMed Pharmaceuticals Inc INM



NDAQ:INM - Post by User

Bullboard Posts
Post by stockman691on Jan 18, 2017 9:09am
99 Views
Post# 25721574

HUGE BOD hire!

HUGE BOD hire!

InMed Pharmaceuticals Appoints Martin Bott to Board of Directors

PR Newswire

CSE: IN
OTCQB: IMLFF

VANCOUVER, Jan. 13, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), today announced that Martin Bott, VP of Corporate Finance and Investment Banking at Eli Lilly & Company, has been appointed to InMed Board of Directors effective immediately. Mr. Bott brings over 28 years of senior financial and executive leadership to InMed's Board of Directors.

"Martin Bott has established a significant leadership position in financial and business expertise with one of the world's leading pharmaceutical companies. His depth of knowledge in navigating the complexities in healthcare finance and operations on a global level will be invaluable to InMed," said Eric A. Adams, President & Chief Executive Officer. "We welcome Martin to our Board and look forward to his strategic counsel as we work towards achieving our many corporate objectives."  

Mr. Bott has a Bachelors of Business / Marketing (Cologne, Germany, 1985) and a Master's in International Business Studies (University of South Carolina, 1988).  He joined Lilly in 1988 and has held roles of increasing responsibility at their headquarters in Indianapolis as well as affiliates in Switzerland, Germany, and the UK.  Prior to his current assignment, Mr. Bott was the CFO for both the Diabetes Business and the Global Manufacturing and Quality organizations.  He has been a member of the Lilly CFO Staff since December 2002.


Bullboard Posts